MX2023008677A - Derivados de urolitinas y métodos para su uso. - Google Patents

Derivados de urolitinas y métodos para su uso.

Info

Publication number
MX2023008677A
MX2023008677A MX2023008677A MX2023008677A MX2023008677A MX 2023008677 A MX2023008677 A MX 2023008677A MX 2023008677 A MX2023008677 A MX 2023008677A MX 2023008677 A MX2023008677 A MX 2023008677A MX 2023008677 A MX2023008677 A MX 2023008677A
Authority
MX
Mexico
Prior art keywords
methods
urolithin derivatives
urolithin
derivatives
compositions
Prior art date
Application number
MX2023008677A
Other languages
English (en)
Inventor
Said Oumouch
Penelope Andreux
Jonathan Mark Sutton
Florent Beaufils
Christopher L Rinsch
Eileen M Seward
Jamie D Knight
Ian Linney
Peter C Sennhenn
Thomas Christian Fessard
Original Assignee
Vandria Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vandria Sa filed Critical Vandria Sa
Publication of MX2023008677A publication Critical patent/MX2023008677A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/10—Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se describen compuestos, composiciones, y métodos útiles para el tratamiento de enfermedades neuronales y mitocondriales.
MX2023008677A 2021-01-27 2022-01-27 Derivados de urolitinas y métodos para su uso. MX2023008677A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163142333P 2021-01-27 2021-01-27
PCT/IB2022/000049 WO2022162471A1 (en) 2021-01-27 2022-01-27 Urolithin derivatives and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2023008677A true MX2023008677A (es) 2023-10-03

Family

ID=80595402

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008677A MX2023008677A (es) 2021-01-27 2022-01-27 Derivados de urolitinas y métodos para su uso.

Country Status (11)

Country Link
US (4) US11820751B2 (es)
EP (1) EP4284781A1 (es)
JP (1) JP2024503753A (es)
KR (1) KR20230153533A (es)
CN (1) CN117015530A (es)
AU (1) AU2022212883A1 (es)
BR (1) BR112023014973A2 (es)
CA (1) CA3206062A1 (es)
IL (1) IL304680A (es)
MX (1) MX2023008677A (es)
WO (1) WO2022162471A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3206062A1 (en) 2021-01-27 2022-08-04 Said Oumouch Urolithin derivatives and methods of use thereof
WO2023228994A1 (ja) * 2022-05-25 2023-11-30 株式会社ダイセル Ｓｉｒｔ３遺伝子発現増強用組成物
WO2024023585A2 (en) * 2022-07-27 2024-02-01 Vandria Sa Urolithin derivatives and therapeutic uses
WO2024025953A2 (en) * 2022-07-27 2024-02-01 Vandria Sa Therapeutic uses of urolithin derivatives

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4463001A (en) 1980-10-20 1984-07-31 Farmitalia Carlo Erba S.P.A. 6-Substituted 6H-dibenzo[b,d]pyran derivatives and process for their preparation
JPH02304080A (ja) 1989-05-17 1990-12-17 Toyo Pharma- Kk ６Ｈ―ジベンゾ［ｂ，ｄ］ピラン―６―オン誘導体，その製法及び用途
EP0586608A1 (en) 1991-05-29 1994-03-16 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
JPH05214334A (ja) 1992-02-05 1993-08-24 Konica Corp 有機薄膜エレクトロルミネッセンス素子
JPH06234753A (ja) 1993-02-10 1994-08-23 Meiji Seika Kaisha Ltd イソオキサゾール化合物およびその塩
JPH07188215A (ja) 1993-12-28 1995-07-25 Meiji Seika Kaisha Ltd アゾール誘導体及びその塩
AU9774298A (en) 1997-09-17 1999-04-05 Merck & Co., Inc. Aryloxymethyl carbapenem antibacterials
US6284753B2 (en) 1998-06-02 2001-09-04 Merck & Co., Inc. Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment
WO2002065984A2 (en) 2001-02-16 2002-08-29 Bristol-Myers Squibb Company Compounds having retinoid-like activity
WO2004073612A2 (en) 2003-02-13 2004-09-02 Merck & Co. Inc. Estrogen receptor modulators
EP1618101B1 (de) * 2003-02-25 2017-12-20 Merck Patent GmbH Benzochromenderivate
EP1652841A1 (en) 2004-04-30 2006-05-03 Switch Biotech Aktiengesellschaft Novel phenantridine analogues and their use as inhibitors of hyperproliferation of T cells and/or keratinocytes
EP2214670A2 (en) 2007-11-02 2010-08-11 Taiga Biotechnologies, Inc. Compounds for treating abnormal cellular proliferation
CN101654401B (zh) 2008-08-18 2013-06-05 中国人民解放军军事医学科学院毒物药物研究所 不对称联苯类化合物、含有它的药物组合物及其用途
DE102009022309A1 (de) 2009-05-22 2010-11-25 Merck Patent Gmbh Flüssigkristallanzeige
RU2576032C2 (ru) 2009-07-24 2016-02-27 Амазентис Са Соединения, композиции и способы защиты здоровья головного мозга при нейродегенеративных расстройствах
KR20120115565A (ko) 2010-02-01 2012-10-18 온콜리스 바이오파마 가부시키가이샤 Ｃ형 간염 치료제
SG10201602286RA (en) 2010-12-23 2016-04-28 Amazentis Sa Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
SG191759A1 (en) 2010-12-30 2013-08-30 Enanta Pharm Inc Phenanthridine macrocyclic hepatitis c serine protease inhibitors
KR20140002735A (ko) * 2011-02-09 2014-01-08 산텐 세이야꾸 가부시키가이샤 3-히드록시-6H-벤조[c]크로멘-6-온 유도체 및 그 제조 방법
US9173395B2 (en) 2011-07-04 2015-11-03 Bayer Intellectual Property Gmbh Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants
AU2012311702B2 (en) 2011-09-22 2017-07-13 Merck Sharp & Dohme B.V. FSH receptor antagonists
KR102317160B1 (ko) 2012-06-27 2021-10-25 아마젠티스 에스에이 우롤리틴 또는 이의 전구체를 투여에 의한 자가포식 향상 또는 장수 증가
BR112016009757A8 (pt) 2013-10-29 2018-01-30 Medivir Ab “inibidores do vírus sincicial respiratório com base em quinazolina”
WO2015100213A2 (en) 2013-12-23 2015-07-02 Amazentis Sa Process-scale synthesis of urolithins
GB201323008D0 (en) 2013-12-24 2014-02-12 Amazentis As Compounds and uses thereof
CN103772228B (zh) 2014-01-16 2016-01-20 华东理工大学 联苯双酰胺类化合物及其制备和用途
WO2015140799A1 (en) 2014-03-18 2015-09-24 Carmel-Haifa University Economic Corp. Ltd Methods for improving cognitive function via modulation of quinone reductase 2
WO2015154047A1 (en) * 2014-04-03 2015-10-08 Restorgenex Corporation Novel methods
JP2016162983A (ja) 2015-03-04 2016-09-05 ダイキン工業株式会社 エッチング処理用組成物及びエッチング処理方法
CN105085463B (zh) * 2015-08-25 2017-06-16 浙江医学高等专科学校 一种微波快速制备联芳基七元内酯的方法
GB201515391D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
GB201515387D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
JP7182837B2 (ja) 2015-12-24 2022-12-05 アマゼンティス エスアー ニコチンアミドリボシド及びウロリチンを含む組成物
US10829452B2 (en) 2016-12-22 2020-11-10 Global Blood Therapeutics, Inc. Histone methyltransferase inhibitors
CN106632214B (zh) 2016-12-28 2019-01-25 西北大学 一种大麻酚类化合物的合成方法
KR102305710B1 (ko) 2017-03-06 2021-09-30 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 Gpr84 수용체 길항제 및 이의 용도
JP2020510678A (ja) 2017-03-08 2020-04-09 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ 対象におけるマイトファジーを改善するための方法
EP3592424A1 (en) * 2017-03-08 2020-01-15 Amazentis SA Methods for improving mitophagy in subjects
WO2018162645A1 (en) 2017-03-08 2018-09-13 Amazentis Sa Skin treatment methods
CN109761902B (zh) 2017-11-09 2022-06-10 四川大学 6-菲啶酮衍生物及其制备方法和用途
CA3092106A1 (en) 2018-02-27 2019-09-06 Amazentis Sa Process-scale synthesis of urolithin a
JP2021522296A (ja) 2018-04-30 2021-08-30 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ 免疫増強剤としてのウロリチンａ
KR20210042264A (ko) * 2018-05-15 2021-04-19 유니버시티 오브 루이빌 리서치 파운데이션, 인코포레이티드 요법에서의 사용을 위한 우롤리틴 a 및 그의 유도체
PL245399B1 (pl) * 2018-11-29 2024-07-15 Univ Warszawski Medyczny Kompozycja farmaceutyczna zawierająca urolitynę A lub jej pochodną do zastosowania zewnętrznego miejscowego w leczeniu, hamowaniu i zapobieganiu chorobom skóry i błon śluzowych o podłożu zapalnym
WO2020124206A1 (en) 2018-12-18 2020-06-25 University Of Manitoba Metal complexes, methods of making the same, and uses thereof
GB201912107D0 (en) 2019-08-22 2019-10-09 Amazentis Sa Combination
GB201916046D0 (en) 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
CN110862368B (zh) * 2019-11-25 2021-06-15 浙江工业大学 一种苯并香豆素类化合物的光催化氧化合成方法
CA3206062A1 (en) 2021-01-27 2022-08-04 Said Oumouch Urolithin derivatives and methods of use thereof

Also Published As

Publication number Publication date
IL304680A (en) 2023-09-01
US11820751B2 (en) 2023-11-21
US20220259173A1 (en) 2022-08-18
CN117015530A (zh) 2023-11-07
KR20230153533A (ko) 2023-11-06
US20240158364A1 (en) 2024-05-16
CA3206062A1 (en) 2022-08-04
US20240158365A1 (en) 2024-05-16
AU2022212883A1 (en) 2023-08-17
BR112023014973A2 (pt) 2023-11-07
WO2022162471A1 (en) 2022-08-04
US20240158363A1 (en) 2024-05-16
EP4284781A1 (en) 2023-12-06
JP2024503753A (ja) 2024-01-26

Similar Documents

Publication Publication Date Title
MX2023008677A (es) Derivados de urolitinas y métodos para su uso.
CO2021003074A2 (es) Derivados de 6-(4-amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il)-3-(2,3-diclorofenil)-2-metilpirimidin-4(3h)-ona y compuestos relacionados como inhibidores de ptpn11 (shp2) para el tratamiento del cáncer
PH12021551274A1 (en) 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
PH12020551927A1 (en) Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX2019007416A (es) Derivados de benzooxazol como inmunomoduladores.
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
MX2022010082A (es) Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo.
MX2021010888A (es) Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis.
MX2020011234A (es) Moduladores de receptor similar al dominio de oligomerizacion de union a nucleotidos que contiene dominio de pirina 3 (nlrp3).
CR20230362A (es) Inhibidores de cdk2 y métodos de uso de los mismos
MX2022005298A (es) Compuestos intermediarios de sintesis de inhibidores de a2a.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2019007788A (es) Composiciones y metodos para tratar condiciones de la piel mediante el uso de luz y clorhidrato de glucosamina.
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
ZA202106519B (en) Caspase inhibitors and methods of use thereof
MX2022002446A (es) Compuestos de pirrolopirimidina inhibidores de perk.
MX2018015548A (es) Inhibidores mitocondriales para el tratamiento de trastornos de proliferacion.
MX2022016179A (es) Compuestos y metodos para tratar infecciones fungicas.
MX2019000542A (es) Derivados de pirazolilaminobenzimidazol como inhibidores de jak.
MX2022006179A (es) Derivados macrociclicos de indol como inhibidores de mcl-1.
MX2022002443A (es) Compuestos inhibidores de perk.